The Claim
In adolescents with obesity and type 2 diabetes, 36 weeks of weekly administration of Mazdutide 6 mg combined with metformin and insulin was associated with a 37.00% reduction in serum uric acid from 511 to 322 μmol/L, with serum uric acid levels remaining sustained for 6 weeks after discontinuation of treatment.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adolescents with obesity and type 2 diabetes, a weekly injection of Mazdutide 6 mg along with metformin and insulin for 36 weeks lowered blood uric acid levels by 37%, and these lower levels stayed reduced for six weeks after stopping the treatment.
See the scientific wording
In an adolescent with obesity and type 2 diabetes, 36 weeks of weekly Mazdutide 6 mg combined with metformin and insulin was associated with a 37.00% reduction in serum uric acid from 511 to 322 μmol/L, with sustained levels 6 weeks after discontinuation.
A drug that activates two receptors in the body causes the kidneys to flush out more uric acid and the liver to make less of it, leading to a lasting drop in blood uric acid levels.
What the research says
1 studyA teen with obesity and diabetes got a weekly shot called Mazdutide along with his other meds, and his blood uric acid dropped by 37%—and even after stopping the shot for six weeks, the level stayed low. The study confirms this happened.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.